Impact of Atorvastatin on Prostate Cancer Progression During ADT
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This randomized double-blind placebo-controlled trial tests whether intervention with
atorvastatin delays development of castration resistance compared to placebo during androgen
deprivation therapy (ADT) for prostate cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Tampere University Hospital
Collaborators:
Central Finland Hospital District Fimlab laboratories Helsinki University Central Hospital Kuopio University Hospital Tartu University Hospital Turku University Hospital University of Aarhus